Fig. 7
From: Metabolic reprogramming in amyotrophic lateral sclerosis ependymal stem cells by FM19G11 nanotherapy
Glucose, glutamate and glutathione-related pathway metabolites in epSPCs ALS, and B6SJL cells. Levels of the glucose, glutamate, and glutathione-related pathway metabolites in epSPCs from B6SJL (pink), untreated G93A-SOD1 (yellow) and G93A-SOD1 treated cells with FM19G11-loaded nanovectors (light blue) at 18 weeks (N = 5 for each group). Data information: Data are expressed as relative to control. The Kruskal-Wallis analysis was used to compare each metabolite among untreated and treated epSPCs ALS and B6SJL cells. *p < 0.05, **p < 0.01, ***p < 0.001.
